[1]安德明,郑培永,季光.不同治则中药复方对胆汁淤积性肝纤维化大鼠尿激酶型纤溶酶原激活剂的影响[J].中国中医药信息杂志,2009,16(5):31-34.
 AN De-ming,ZHENG Pei-yong,JI Guang.Effect of Chinese Hebal Compound of Different Treating Principles on uPA of Cholestasis-induced Liver Fibrosis Rat[J].zhongguo zhongyiyao xinxi zazhi,2009,16(5):31-34.
点击复制

不同治则中药复方对胆汁淤积性肝纤维化大鼠尿激酶型纤溶酶原激活剂的影响

参考文献/References:

[1] 孙杨忠,耿小平.阻塞性黄疸大鼠胆总管直径、压力及血清胆红素代谢变化的观察[J].肝胆外科杂志,2003,11(2):141-142.

[2] Leyland H, Gentry J, Arthur MJ, et al. The plasminogen-activating system in hepatic stellate cells[J]. Hepatology, 1996,24:1172-1178.

[3] Brauer PR. MMPs-role in cardiovascular development and disease[J]. Front Biosci,2006,11:447-478.

[4] Malermud CJ. Matrix metalloproteinases (MMPs) in health and disease:an overview[J]. Front Biosci,2006,11:1696-1701.

[5] Irigoyen JP, Munoz-Canoves P, Montero L, et al. The plasminogen activator system:biology and regulation[J]. Cell Mol Life Sci, 1999,56:104-132.

[6] Zhang LP, Takahara T, Yata Y, et al. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats:role of stellate cells[J]. J Hepatol, 1999,31:703-711.

[7] 王 兵,朱平生.茵陈四苓散防治胆管结扎大鼠肝纤维化的实验研究[J].河南中医,2005,25(7):20-22.

相似文献/References:

[1]吉兰芳,王梦梦,崔树娜.基于网络药理学方法的二至丸治疗肝肾阴虚型崩漏作用机制研究[J].中国中医药信息杂志,2020,27(4):78.[doi:10.3969/j.issn.1005-5304.201905215]
 JI Lanfang,WANG Mengmeng,CUI Shuna.Mechanism of Erzhi Pills on Liver-kidney Yin Deficiency Metrorrhagia Based on Network Pharmacology[J].zhongguo zhongyiyao xinxi zazhi,2020,27(5):78.[doi:10.3969/j.issn.1005-5304.201905215]

备注/Memo

基金项目:教育部新世纪优秀人才支持计划(NCET-07-0563);上海市教委重点学科资助(J50305)

更新日期/Last Update: